The miR-124-prolyl hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression

Oncotarget

Volumn 5, Issue 16, 2014, Pages 6654-6669

  Chakravarthi, Balabhadrapatruni V S K ^a,b   Pathi, Satya S ^a,b   Goswami, Moloy T ^a,b   Cies´lik, Marcin ^a,b   Zheng, Heng ^a   Nallasivam, Sivakumar ^a   Arekapudi, Subramanyeswara R ^a,c   Jing, Xiaojun ^a,b   Siddiqui, Javed ^a,b   Athanikar, Jyoti ^a,b   Carskadon, Shannon L ^a,b   Lonigro, Robert J ^a,b   Kunju, Lakshmi P ^a,b   Chinnaiyan, Arul M ^a,b   Palanisamy, Nallasivam ^a,b   Varambally, Sooryanarayana ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c PROVIDENCE HOSPITAL   (United States)

Author keywords

Alpha polypeptide I; Matrix metalloprotease 1; Metastasis; MicroRNA; Progression; Prolyl 4 hydroxylase; Prostate cancer

Indexed keywords

BINDING PROTEIN; C TERMINAL BINDING PROTEIN 1; FIBRONECTIN LEUCINE RICH TRANSMEMBRANE PROTEIN 3; GELATINASE A; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERSTITIAL COLLAGENASE; MEMBRANE PROTEIN; MESSENGER RNA; MICRORNA 124; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROLYL 4 HYDROXYLASE ALPHA POLYPEPTIDE 2; PROLYL 4 HYDROXYLASE ALPHA POLYPEPTIDE I; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; FLRT3 PROTEIN, HUMAN; MICRORNA; MIRN124 MICRORNA, HUMAN; MMP1 PROTEIN, HUMAN; P4HA1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME REGULATION; GENE; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE LOCUS; GENE OVEREXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; P4HA1 GENE; PATHOPHYSIOLOGY; PROMOTER REGION; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE MICROARRAY; TUMOR INVASION; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; BIOSYNTHESIS; DISEASE COURSE; ENZYMOLOGY; GENE EXPRESSION; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; HUMAN; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; GENE EXPRESSION; HEK293 CELLS; HETEROGRAFTS; HUMANS; MALE; MATRIX METALLOPROTEINASE 1; MEMBRANE PROTEINS; MICE; MICE, NUDE; MICRORNAS; PROCOLLAGEN-PROLINE DIOXYGENASE; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84907075302     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2208     Document Type: Article

References (53)

1. Siegel R, Ma J, Zou Z and Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. 2014; 64(1):9-29.
2. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Jr., Lu L, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503-511.
3. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA and Chinnaiyan AM. Delineation of prognostic biomarkers in prostate cancer. Nature. 2001; 412(6849):822-826.
4. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, et al. A gene-expression signature as a predictor of survival in breast cancer. The New England journal of medicine. 2002; 347(25):1999-2009.
5. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R and Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415(6871):530-536.
6. Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, Minden MD, Sallan SE, Lander ES, Golub TR and Korsmeyer SJ. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nature genetics. 2002; 30(1):41-47.
7. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA and Chinnaiyan AM. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002; 419(6907):624-629.
8. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M and Rajewsky N. Combinatorial microRNA target predictions. Nat Genet. 2005; 37(5):495-500.
9. Ferreira PG, Jares P, Rico D, Gomez-Lopez G, Martinez-Trillos A, Villamor N, Ecker S, Gonzalez-Perez A, Knowles DG, Monlong J, Johnson R, Quesada V, Djebali S, Papasaikas P, Lopez-Guerra M, Colomer D, et al. Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia. Genome research. 2014; 24(2):212-226.
10. Palanisamy N, Ateeq B, Kalyana-Sundaram S, Pflueger D, Ramnarayanan K, Shankar S, Han B, Cao Q, Cao X, Suleman K, Kumar-Sinha C, Dhanasekaran SM, Chen YB, Esgueva R, Banerjee S, LaFargue CJ, et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nature medicine. 2010; 16(7):793-798.
11. Myllyharju J. Prolyl 4-hydroxylases, the key enzymes of collagen biosynthesis. Matrix Biol. 2003; 22(1):15-24.
12. Myllyharju J and Kivirikko KI. Collagens, modifying enzymes and their mutations in humans, flies and worms. Trends Genet. 2004; 20(1):33-43.
13. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-674.
14. Gilkes DM, Bajpai S, Chaturvedi P, Wirtz D and Semenza GL. Hypoxia-inducible Factor 1 (HIF-1) Promotes Extracellular Matrix Remodeling under Hypoxic Conditions by Inducing P4HA1, P4HA2, and PLOD2 Expression in Fibroblasts. J Biol Chem. 2013; 288(15):10819-10829.
15. Gilkes DM, Chaturvedi P, Bajpai S, Wong CC, Wei H, Pitcairn S, Hubbi ME, Wirtz D and Semenza GL. Collagen prolyl hydroxylases are essential for breast cancer metastasis. Cancer Res. 2013; 73(11):3285-3296.
16. Wang R, Asangani IA, Chakravarthi BV, Ateeq B, Lonigro RJ, Cao Q, Mani RS, Camacho DF, McGregor N, Schumann TE, Jing X, Menawat R, Tomlins SA, Zheng H, Otte AP, Mehra R, et al. Role of transcriptional corepressor CtBP1 in prostate cancer progression. Neoplasia. 2012; 14(10):905-914.
17. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012; 487(7406):239-243.
18. Prensner JR, Iyer MK, Balbin OA, Dhanasekaran SM, Cao Q, Brenner JC, Laxman B, Asangani IA, Grasso CS, Kominsky HD, Cao X, Jing X, Wang X, Siddiqui J, Wei JT, Robinson D, et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nature biotechnology. 2011; 29(8):742-749.
19. Kalyana-Sundaram S, Kumar-Sinha C, Shankar S, Robinson DR, Wu YM, Cao X, Asangani IA, Kothari V, Prensner JR, Lonigro RJ, Iyer MK, Barrette T, Shanmugam A, Dhanasekaran SM, Palanisamy N and Chinnaiyan AM. Expressed pseudogenes in the transcriptional landscape of human cancers. Cell. 2012; 149(7):1622-1634.
20. Vanaja DK, Cheville JC, Iturria SJ and Young CY. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res. 2003; 63(14):3877-3882.
21. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, McDonald C, Thomas R, Dhir R, Finkelstein S, Michalopoulos G, Becich M and Luo JH. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2004; 22(14):2790-2799.
22. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP and Burge CB. Prediction of mammalian microRNA targets. Cell. 2003; 115(7):787-798.
23. John B, Enright AJ, Aravin A, Tuschl T, Sander C and Marks DS. Human MicroRNA targets. PLoS biology. 2004; 2(11):e363.
24. Lewis BP, Burge CB and Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120(1):15-20.
25. Bentovim L, Amarilio R and Zelzer E. HIF1alpha is a central regulator of collagen hydroxylation and secretion under hypoxia during bone development. Development. 2012; 139(23):4473-4483.
26. Cao P, Deng Z, Wan M, Huang W, Cramer SD, Xu J, Lei M and Sui G. MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta. Molecular cancer. 2010; 9:108.
27. Du R, Sun W, Xia L, Zhao A, Yu Y, Zhao L, Wang H, Huang C and Sun S. Hypoxia-induced down-regulation of microRNA-34a promotes EMT by targeting the Notch signaling pathway in tubular epithelial cells. PLoS One. 2012; 7(2):e30771.
28. He M, Wang QY, Yin QQ, Tang J, Lu Y, Zhou CX, Duan CW, Hong DL, Tanaka T, Chen GQ and Zhao Q. HIF-1alpha downregulates miR-17/20a directly targeting p21 and STAT3: a role in myeloid leukemic cell differentiation. Cell death and differentiation. 2013; 20(3):408-418.
29. Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ, Davuluri R, Liu CG, Croce CM, Negrini M, Calin GA and Ivan M. A microRNA signature of hypoxia. Molecular and cellular biology. 2007; 27(5):1859-1867.
30. Gray MJ, Zhang J, Ellis LM, Semenza GL, Evans DB, Watowich SS and Gallick GE. HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene. 2005; 24(19):3110-3120.
31. Hu CJ, Iyer S, Sataur A, Covello KL, Chodosh LA and Simon MC. Differential regulation of the transcriptional activities of hypoxia-inducible factor 1 alpha (HIF-1alpha) and HIF-2alpha in stem cells. Molecular and cellular biology. 2006; 26(9):3514-3526.
32. Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I and Inazawa J. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis. 2010; 31(5):766-776.
33. Gebauer K, Peters I, Dubrowinskaja N, Hennenlotter J, Abbas M, Scherer R, Tezval H, Merseburger AS, Stenzl A, Kuczyk MA and Serth J. Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma. British journal of cancer. 2013; 108(1):131-138.
34. Sato F, Tsuchiya S, Meltzer SJ and Shimizu K. MicroRNAs and epigenetics. The FEBS journal. 2011; 278(10):1598-1609.
35. Wang P, Chen L, Zhang J, Chen H, Fan J, Wang K, Luo J, Chen Z, Meng Z and Liu L. Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1. Oncogene. 2014; 33(4):514-524.
36. Asangani IA, Ateeq B, Cao Q, Dodson L, Pandhi M, Kunju LP, Mehra R, Lonigro RJ, Siddiqui J, Palanisamy N, Wu YM, Cao X, Kim JH, Zhao M, Qin ZS, Iyer MK, et al. Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. Molecular cell. 2013; 49(1):80-93.
37. Cao Q, Mani RS, Ateeq B, Dhanasekaran SM, Asangani IA, Prensner JR, Kim JH, Brenner JC, Jing X, Cao X, Wang R, Li Y, Dahiya A, Wang L, Pandhi M, Lonigro RJ, et al. Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell. 2011; 20(2):187-199.
38. Karaulanov E, Bottcher RT, Stannek P, Wu W, Rau M, Ogata S, Cho KW and Niehrs C. Unc5B interacts with FLRT3 and Rnd1 to modulate cell adhesion in Xenopus embryos. PLoS One. 2009; 4(5):e5742.
39. Pulukuri SM and Rao JS. Matrix metalloproteinase-1 promotes prostate tumor growth and metastasis. International journal of oncology. 2008; 32(4):757-765.
40. Odake S, Morita Y, Morikawa T, Yoshida N, Hori H and Nagai Y. Inhibition of matrix metalloproteinases by peptidyl hydroxamic acids. Biochemical and biophysical research communications. 1994; 199(3):1442-1446.
41. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S and Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell. 2005; 120(3):303-313.
42. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, Varambally S, Ghosh D and Chinnaiyan AM. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007; 9(2):166-180.
43. Chang CJ, Yang JY, Xia W, Chen CT, Xie X, Chao CH, Woodward WA, Hsu JM, Hortobagyi GN and Hung MC. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling. Cancer Cell. 2011; 19(1):86-100.
44. Koh MY, Spivak-Kroizman TR and Powis G. HIF-1alpha and cancer therapy. Recent results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer. 2010; 180:15-34.
45. Kuppuswamy M, Vijayalingam S, Zhao LJ, Zhou Y, Subramanian T, Ryerse J and Chinnadurai G. Role of the PLDLS-binding cleft region of CtBP1 in recruitment of core and auxiliary components of the corepressor complex. Molecular and cellular biology. 2008; 28(1):269-281.
46. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, Han B, Tan P, Kumar-Sinha C, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science. 2008; 322(5908):1695-1699.
47. Dong Z, Bonfil RD, Chinni S, Deng X, Trindade Filho JC, Bernardo M, Vaishampayan U, Che M, Sloane BF, Sheng S, Fridman R and Cher ML. Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue. The American journal of pathology. 2005; 166(4):1173-1186.
48. Pratap J, Javed A, Languino LR, van Wijnen AJ, Stein JL, Stein GS and Lian JB. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Molecular and cellular biology. 2005; 25(19):8581-8591.
49. Chen X, Koh E, Yoder M and Gumbiner BM. A protocadherin-cadherin-FLRT3 complex controls cell adhesion and morphogenesis. PLoS One. 2009; 4(12):e8411.
50. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, Cao Q, Prensner JR, Rubin MA, Shah RB, Mehra R and Chinnaiyan AM. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia. 2008; 10(2):177-188.
51. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM and Haussler D. The human genome browser at UCSC. Genome research. 2002; 12(6):996-1006.
52. Deng Y, Liu J, Han G, Lu SL, Wang SY, Malkoski S, Tan AC, Deng C, Wang XJ and Zhang Q. Redox-dependent Brca1 transcriptional regulation by an NADH-sensor CtBP1. Oncogene. 2010; 29(50):6603-6608.
53. Cakouros D, Isenmann S, Cooper L, Zannettino A, Anderson P, Glackin C and Gronthos S. Twist-1 induces Ezh2 recruitment regulating histone methylation along the Ink4A/Arf locus in mesenchymal stem cells. Molecular and cellular biology. 2012; 32(8):1433-1441.